Last reviewed · How we verify

Taejoon Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Taejoon Pharmaceutical Co., Ltd. pipeline: 3 marketed, 0 filed, 16 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 16 Phase 3 3 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Taflotan-S Taflotan-S marketed
TJO-018 (HA 0.15%) TJO-018 (HA 0.15%) marketed Artificial tear / Ocular lubricant Ocular surface (non-receptor mediated) Ophthalmology
Xalost S Xalost S marketed
TJO-087 TJO-087 phase 3 SGLT2 inhibitor SGLT2 Diabetes
TJP-008-1 TJP-008-1 phase 3 SGLT2 inhibitor SGLT2 Diabetes
TJP-008-2 TJP-008-2 phase 3 SGLT2 inhibitor SGLT2 Diabetes
CTP0302-B CTP0302-B phase 3 SGLT2 inhibitor SGLT2 Diabetes
Conventional OST Conventional OST phase 3 Cell therapy / Regenerative medicine Orthopedics / Regenerative Medicine
CTP0302-A CTP0302-A phase 3 SGLT2 inhibitor SGLT2 Diabetes
Diquafosol ophthalmic sodium solution 3% Diquafosol ophthalmic sodium solution 3% phase 3 P2Y2 receptor agonist P2Y2 purinergic receptor Ophthalmology
Cool prep Cool prep phase 3 Osmotic laxative / Bowel preparation agent Gastroenterology
CTP0301-B CTP0301-B phase 3 SGLT2 inhibitor SGLT2 Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allergan · 3 shared drug classes
  2. Chong Kun Dang Pharmaceutical · 3 shared drug classes
  3. Kuhnil Pharmaceutical Co., Ltd. · 2 shared drug classes
  4. Bayer · 2 shared drug classes
  5. Hoffmann-La Roche · 2 shared drug classes
  6. Hospices Civils de Lyon · 2 shared drug classes
  7. Astellas Pharma Inc · 2 shared drug classes
  8. Novartis · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Taejoon Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Taejoon Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/taejoon-pharmaceutical-co-ltd. Accessed 2026-05-16.

Related